MarketsOtherIs the "100% effective against solid tumors" cance
📊 OtherKalshi60/100 confidence

Is the "100% effective against solid tumors" cancer pill AOH1996 paper legit? [see description]

Forecasting market: Is the "100% effective against solid tumors" cancer pill AOH1996 paper legit? [see description]

Alpha Opportunity

40/100
Market Price24%Kalshi
Analyst Estimate70%Analyst research
=
Your Edge+46.0%Bet buy
RecommendedYES0% APY
Trade on Kalshi

Alpha Thesis

📊 Dr. Sarah Chen⚖️ James Kowalski🔬 Dr. Aisha Patel🧠 Marcus WebbUpdated 2026-03-16
60/100
📊Free Summary

We REVISE UP to 70% (from 29%) for the AOH1996 paper being legitimate. Phase 1 clinical trials at City of Hope show real results: 49% tumor shrinkage in pancreatic liver metastases, no significant toxicity, and a new March 2026 NSCLC study (Frontiers in Pharmacology) confirming anti-cancer activity. The original paper appears to be well-supported by subsequent clinical evidence.

📐Key Metrics

1
49% tumor shrinkageClinical EvidenceTwo pancreatic cancer patients showed up to 49% reduction in liver metastases.
2
Phase 1 activeFDA Trial OngoingActive Phase 1 at City of Hope for solid tumors and AML.
3
24% vs. 70%46-Point Edge!Market massively underprices given clinical validation.

Key Findings

  • Phase 1 clinical trials ACTIVE at City of Hope. FDA-approved trials = real drug.
  • 49% tumor shrinkage in pancreatic cancer liver metastases (2 patients, April 2025).
  • No significant toxicity observed. Consistent with preclinical animal studies.
  • New NSCLC study published March 2026 (Frontiers in Pharmacology) confirms anti-cancer activity.
  • PCNA-targeting mechanism has strong scientific basis.
🔒

Full Research Report

Unlock the complete analysis including probability assessment, Bayesian calculations, resolution rigor analysis, and strategic positioning recommendations across 5+ dimensions.

Toggle to Pro in the top bar to access the full report

Alpha Quality Factors

Criteria that determine how exploitable this mispricing is

Edge Magnitude+46.0% raw edge — Strong mispricing
100
Liquidity Health$6K available — Thinner market, size carefully
0
Volume Activity$902 24h volume — Lower activity, watch for stale pricing
0
Time ValueExpires in 12 months — Longer horizon, more uncertainty
40
Analyst Confidence60/100 confidence — Moderate conviction
60

Human Bias Detected

Cognitive biases creating this alpha opportunity

🧠
Information Asymmetry

The crowd may lack specialized knowledge that narrows the true probability range.

Compare Markets

Searching Polymarket, Kalshi, Manifold & Metaculus…

Market Data

Liquidity$6K
24h Volume$902
Expected Return0.0%
Annualized APY0%
Time to Expiry12 months
Risk Levelmedium

Position Sizing

Kelly Criterion (per $1,000 bankroll)

Full Kelly$1457145.7%
½ Kelly ★$72872.8%
¼ Kelly$36436.4%

Payoff Scenarios

InvestWinLose
$100+$32-$100
$250+$79-$250
$500+$158-$500
$1000+$316-$1000

Analysis Team

📊
Dr. Sarah ChenLead Quantitative Analyst
⚖️
James KowalskiRisk & Position Strategist
🔬
Dr. Aisha PatelDomain Research Lead
🧠
Marcus WebbBehavioral Finance Specialist